JP2019526528A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019526528A5 JP2019526528A5 JP2018563618A JP2018563618A JP2019526528A5 JP 2019526528 A5 JP2019526528 A5 JP 2019526528A5 JP 2018563618 A JP2018563618 A JP 2018563618A JP 2018563618 A JP2018563618 A JP 2018563618A JP 2019526528 A5 JP2019526528 A5 JP 2019526528A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antigen
- variable region
- antibody
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662348009P | 2016-06-09 | 2016-06-09 | |
| US62/348,009 | 2016-06-09 | ||
| PCT/US2017/036817 WO2017214547A1 (en) | 2016-06-09 | 2017-06-09 | Anti-tnfrsf25 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019526528A JP2019526528A (ja) | 2019-09-19 |
| JP2019526528A5 true JP2019526528A5 (enExample) | 2020-07-16 |
| JP6961625B2 JP6961625B2 (ja) | 2021-11-10 |
Family
ID=59078259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563618A Expired - Fee Related JP6961625B2 (ja) | 2016-06-09 | 2017-06-09 | 抗ｔｎｆｒｓｆ２５抗体 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10005843B2 (enExample) |
| EP (1) | EP3468998B1 (enExample) |
| JP (1) | JP6961625B2 (enExample) |
| KR (1) | KR102423942B1 (enExample) |
| CN (1) | CN109219620B (enExample) |
| AU (1) | AU2017278192A1 (enExample) |
| BR (1) | BR112018075222A2 (enExample) |
| CA (1) | CA3026652A1 (enExample) |
| DK (1) | DK3468998T3 (enExample) |
| IL (1) | IL263406B2 (enExample) |
| MX (1) | MX389320B (enExample) |
| RU (1) | RU2746314C2 (enExample) |
| SG (1) | SG11201810853UA (enExample) |
| WO (1) | WO2017214547A1 (enExample) |
| ZA (1) | ZA201808317B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101982899B1 (ko) | 2011-09-30 | 2019-05-27 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | ＴＬ1ａ에 대한 항체 및 그의 용도 |
| SG11201705844SA (en) * | 2015-02-06 | 2017-08-30 | Heat Biologics Inc | Vector co-expressing vaccine and costimulatory molecules |
| TWI703158B (zh) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CA3148564A1 (en) * | 2019-08-30 | 2021-03-04 | Matthew M. Seavey | Methods of treating cancer using tnfrsf25 antibodies |
| CA3151319A1 (en) * | 2019-09-26 | 2021-04-01 | Matthew M. Seavey | Tnfrsf25-mediated treatments of immune diseases and disorders |
| WO2022212668A1 (en) * | 2021-03-31 | 2022-10-06 | Heat Biologics, Inc. | Methods and compositions related to tnfrsf25/dr3 agonists |
| CN119256009A (zh) * | 2022-06-17 | 2025-01-03 | 塞莱克辛有限公司 | 与人dr3特异性结合的抗体及其用途 |
| CN120399074B (zh) * | 2023-06-02 | 2025-12-30 | 安徽金百奥生物科技有限公司 | 一种与人dr3胞外域高亲和力的纳米抗体 |
| GB202315963D0 (en) | 2023-10-18 | 2023-11-29 | Cancer Research Tech Ltd | Binding molecules |
| US12319742B1 (en) * | 2024-01-24 | 2025-06-03 | Shattuck Labs, Inc. | Antibodies that bind TNFRSF25 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| CA2082160C (en) | 1991-03-06 | 2003-05-06 | Mary M. Bendig | Humanised and chimeric monoclonal antibodies |
| AU669124B2 (en) | 1991-09-18 | 1996-05-30 | Kyowa Hakko Kirin Co., Ltd. | Process for producing humanized chimera antibody |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| GB9125979D0 (en) | 1991-12-06 | 1992-02-05 | Wellcome Found | Antibody |
| CA2130436C (en) | 1992-02-19 | 2001-04-10 | John S. Abrams | Cloning and expression of humanized monoclonal antibodies against human interleukin-4 |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5705154A (en) | 1995-03-08 | 1998-01-06 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-4 |
| WO2005018571A2 (en) | 2003-08-20 | 2005-03-03 | University Of Miami | Compositions and methods for treating inflammatory lung disease |
| US7612179B2 (en) | 2003-11-28 | 2009-11-03 | Astrazeneca Ab | antibodies binding to a C-terminal fragment of apoliopoprotein E |
| AU2006284922B2 (en) | 2005-08-30 | 2012-01-19 | University Of Miami | Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists and immunotoxins |
| MX2009003306A (es) | 2006-10-02 | 2009-04-23 | Medarex Inc | Anticuerpos humanos que se unen a cxcr4 y sus usos. |
| FR2907341B1 (fr) | 2006-10-18 | 2012-08-17 | Pf Medicament | Utilisation d'un anticorps anti-cd151 pour le traitement du cancer |
| WO2010033913A1 (en) | 2008-09-22 | 2010-03-25 | Icb International, Inc. | Antibodies, analogs and uses thereof |
| SG10201502330TA (en) * | 2009-08-03 | 2015-05-28 | Univ Miami | Method for in vivo expansion of t regulatory cells |
| WO2011106707A2 (en) * | 2010-02-26 | 2011-09-01 | Human Genome Sciences, Inc. | Antibodies that specifically bind to dr3 |
| GB201020995D0 (en) | 2010-12-10 | 2011-01-26 | Bioinvent Int Ab | Biological materials and uses thereof |
| JP2013040160A (ja) | 2011-07-01 | 2013-02-28 | Genentech Inc | 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用 |
| US20140193410A1 (en) | 2013-01-09 | 2014-07-10 | University Of Miami | Compositions and Methods for the Regulation of T Regulatory Cells Using TL1A-Ig Fusion Protein |
| RU2551235C2 (ru) * | 2013-08-26 | 2015-05-20 | Илья Владимирович Духовлинов | Гуманизированное моноклональное антитело, специфичное к синдекану-1 |
| CN103592439B (zh) * | 2013-09-03 | 2015-10-21 | 天津亿美诺生物科技有限公司 | 人尿路上皮癌特异性抗体及其应用 |
| US9982057B2 (en) * | 2014-11-17 | 2018-05-29 | Pelican Therapeutics, Inc. | Human TNFRSF25 antibody |
-
2017
- 2017-06-09 CN CN201780034593.5A patent/CN109219620B/zh not_active Expired - Fee Related
- 2017-06-09 JP JP2018563618A patent/JP6961625B2/ja not_active Expired - Fee Related
- 2017-06-09 WO PCT/US2017/036817 patent/WO2017214547A1/en not_active Ceased
- 2017-06-09 CA CA3026652A patent/CA3026652A1/en active Pending
- 2017-06-09 US US15/618,993 patent/US10005843B2/en active Active
- 2017-06-09 MX MX2018014716A patent/MX389320B/es unknown
- 2017-06-09 SG SG11201810853UA patent/SG11201810853UA/en unknown
- 2017-06-09 IL IL263406A patent/IL263406B2/en unknown
- 2017-06-09 KR KR1020187035804A patent/KR102423942B1/ko not_active Expired - Fee Related
- 2017-06-09 DK DK17731434.1T patent/DK3468998T3/da active
- 2017-06-09 EP EP17731434.1A patent/EP3468998B1/en active Active
- 2017-06-09 AU AU2017278192A patent/AU2017278192A1/en not_active Abandoned
- 2017-06-09 RU RU2018143977A patent/RU2746314C2/ru active
- 2017-06-09 BR BR112018075222-3A patent/BR112018075222A2/pt not_active IP Right Cessation
-
2018
- 2018-04-27 US US15/964,775 patent/US10683359B2/en not_active Expired - Fee Related
- 2018-12-10 ZA ZA2018/08317A patent/ZA201808317B/en unknown
-
2020
- 2020-05-14 US US16/874,290 patent/US20210017287A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019526528A5 (enExample) | ||
| TWI902626B (zh) | 嵌合抗原及t細胞受體以及使用方法 | |
| US20250361312A1 (en) | Fc binding fragments comprising an ox40 antigen-binding site | |
| CN107847587B (zh) | Cd30×cd16抗体与pd-1拮抗剂的联合药物 | |
| JP2024019415A (ja) | Ｃｄ１３７及びｏｘ４０に結合する抗体分子 | |
| US20240066040A1 (en) | Ep4 inhibitors and use thereof | |
| TW201841652A (zh) | 靶向ｐｄ－１、ｔｉｍ－３及ｌａｇ－３的組合療法 | |
| RU2018143977A (ru) | Антитела анти-tnfrsf25 | |
| JP7713390B2 (ja) | がん治療のための免疫療法 | |
| US20190183825A1 (en) | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | |
| HRP20171315T1 (hr) | Optimizacija humanih antitijela koja vezuju limfocitni aktivacijski gen-3 (lag-3), i njihove primjene | |
| RS59134B1 (sr) | Anti-b7-h1 i anti-ctla-4 antitela za tretman nesitnoćelijskog kancera pluća | |
| WO2016154621A1 (en) | SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF | |
| JP2021534088A (ja) | 免疫療法とｍｄｍ２阻害剤の併用 | |
| JP2017537892A5 (enExample) | ||
| JP2018535204A (ja) | Ｃｄ８０細胞外ドメインポリペプチドと、がん治療でのそれらの使用 | |
| TW201625270A (zh) | 用於治療贅瘤形成的治療組合及方法 | |
| JP2021524478A (ja) | 抗体分子 | |
| JP2019514846A (ja) | 免疫チェックポイントモジュレーターとのｔ細胞リダイレクティング多機能抗体の組み合わせとその使用 | |
| CA2922251C (en) | Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics | |
| JP2022534297A (ja) | 抗ｂ７－ｈ３抗体 | |
| CA3177488A1 (en) | Compositions and methods for tcr reprogramming using cd70 specific fusion proteins | |
| Li et al. | Bispecific antibody targeting both B7-H3 and PD-L1 exhibits superior antitumor activities | |
| CA3153777A1 (en) | Quantitative spatial profiling for lag-3 antagonist therapy | |
| TWI865617B (zh) | 抗原結合蛋白 |